Table 1.
Randomization, participants and results of screening per centre (core ages, cut-off date December 31, 2008).
| ERSPC – Randomization, participants and results of screening per centre (core ages, cut-off date December 31, 2008) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Netherlands | Belgium | Sweden | Finland | Italy | Spain | Switzerland | Total1 Excluding France |
France- Herault |
France- Tarn |
Total | |
|
|
|
||||||||||
| Period of randomization |
Nov 1993 – March 2000 |
June 1991- Dec 2003 |
31 Dec 2004 |
Jan 1996- Jan 1999 |
Oct 1996 – Oct 2000 |
Feb 1996 – June 1999 |
Sep 1998 - Aug 2003 |
June 2003 – Mar 2005 |
Dec 2000 – June 2004 |
||
|
| |||||||||||
| Randomized – N | 34,833 | 8,562 | 11,852 | 80,379 | 14,517 | 2,197 | 9,903 | 162,243 | 57,658 | 21,356 | 241,257 |
| - screening | 17,443 (50.1%) | 4,307 (50.3%) | 5,901 (49.9%) | 31,970 (39.8%) | 7,266 (50.1%) | 1,056 (48.1%) | 4,948 (50.0) | 72,891 (44.9) | 28,792 (49.9) | 10,886 (51.0) | 112,569 (46.7) |
| - control | 17,390 (49.9%) | 4,255 (49.7%) | 5,951 (50.1%) | 48,409 (60.2%) | 7,251 (49.9%) | 1,141 (51.9%) | 4,955 (50.0) | 89,352 (55.1) | 28,866 (50.1) | 10,470 (49.0) | 128,688 (53.3) |
|
| |||||||||||
| Screened at least once N (%) | 16502 (94.6) | 3908 (90.7) | 4484 (76.0) | 23771 (74.4) | 5730 (78.9) | 1056 (100) | 4793 (96.9) | 60244 (82.6) | 7164 (24.9) | 4005 (36.8) | 71413 (63.4) |
| Screen tests done – N | 37375 | 6438 | 15474 | 52142 | 12731 | 1846 | 10683 | 136689 | 7164 | 4005 | 147858 |
| Positive tests – N (%) | 8892 (23.8%) | 1055 (16.4%) | 2897 (18.7%) | 5925 (11.4) | 1443 (11.3) | 354 (19.2) | 2299 (21.5) | 22865 (16.7) | 1091 (15.2) | 614 (15.3) | 24570 (16.6) |
| Biopsies – N (% of screen positive) | 7989 (89.8%) | 750 (71.1%) | 2509 (86.6%) | 5397 (91.1) | 902 (62.5) | 263 (74.3) | 1836 (79.9) | 19646 (85.9) | 315 (28.9) | 352 (57.3) | 20313 (82.7) |
|
| |||||||||||
| Prostate cancers | |||||||||||
| Screening cohort total – N | 2028 | 420 | 759 | 2838 | 374 | 69 | 475 | 6963 | 885 | 497 | 8345 |
| Screen detected N | 1730 | 187 | 576 | 1631 | 197 | 60 | 376 | 4757 | 163 | 112 | 5032 |
| Interval and Non attender N | 298 | 233* | 183 | 1207 | 177 | 9 | 99 | 2206 | 722 | 385 | 3313 |
| PPV (S det cancers/biopsy, %) | 21.7 | 24.9 | 23.0 | 30.2 | 21.8 | 22.8 | 20.5 | 24.2 | 51.7 | 31.8 | 24.8 |
| Cumulative incidence (total cancers / all rand. To S arm, %) | 11.6 | 9.8 | 12.9 | 8.9 | 5.1 | 6.5 | 9.6 | 9.6 | 3.1 | 4.6 | 7.4 |
|
| |||||||||||
| Prostate cancers | |||||||||||
| Control group – N | 896 | 311 | 507 | 3175 | 257 | 24 | 226 | 5396 | 782 | 443 | 6621 |
| Cumulative incidence (%) | (5.2) | (7.3) | (8.5) | (6.6) | (3.5) | (2.1) | (4.6) | (6.0) | (2.7) | (4.2) | (5.1) |
|
| |||||||||||
| Mean follow up (years) | 10.7 | 11.1 | 12.5 | 10.4 | 9.9 | 10.4 | 7.9 | 10.5 | 4.3 | 5.5 | 8.6 |
| Median follow-up (years) | 11.1 | 12.1 | 14.0 | 11.0 | 10.7 | 10.7 | 8.2 | 11.0 | 4.4 | 5.5 | 9.8 |
*
median screening interval of 6 years between rounds 1 and 2
Interval PC are cases that were clinically detected during the screening interval. Non-attender PC are clinically detected cases in men who refused screening.
1
Excludes the 145 men who died before randomisation